Nippon India Pharma Fund

Ans. The Nippon India Pharma Fund has an AUM of ₹7637.04 Cr as on 6/27/2025. The scheme has delivered CAGR returns for the past 3 years against a category average of 25.93%. The risk is Very High against the category average of 99.7.

Ans. Mutual fund taxation depends on the scheme type and investment holding period.
Taxation on equity funds: For equity funds (funds that invest at least 65% of the corpus in Indian stocks), if the holding period is more than 12 months, LTCG (Long Term Capital Gains) tax is applicable. For units sold within 12 months of purchase, STCG (Short Term Capital Gains) Tax is applicable.
LTCG tax on equity-oriented schemes is 12.5% on capital gains over ₹1.25 lakh (as per the latest update in Budget 2024).
STCG tax applicable on the sale of units of equity-oriented mutual fund schemes is 20%.

Ans. There is no lock-in period applicable on Nippon India Pharma Fund.

Ans. The expense ratio of Nippon India Pharma Fund is 1.82%.